PTIX

Protagenic Therapeutics, Inc. NASDAQ Listed Apr 27, 2021

Healthcare ·Biotechnology ·US · protagenic.com

$0.58

Mkt Cap $1.0M

52w Low $0.25 2.4% of range 52w High $14.28

50d MA $0.61 200d MA $1.81

P/E (TTM) -0.2x

EV/EBITDA -0.4x

P/B —

Debt/Equity -1.3x

ROE 114.2%

P/FCF -0.6x

RSI (14) —

ATR (14) —

Beta 0.47

50d MA $0.61

200d MA $1.81

Avg Volume 8.6K

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.

SIC Code

2834

CIK (SEC)

1022899

Phone

212 994 8200

149 Fifth Avenue · New York City, NY 10010 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 9, 2026	AMC	-4.48	-0.47	+89.5%	0.42	+6.9%	+16.4%	+0.0%	+0.0%	+0.0%	+0.0%	—
Nov 26, 2025	AMC	—	-0.47	—	2.23	-14.3%	-4.5%	-8.5%	-3.1%	-4.2%	-7.2%	—
Aug 18, 2025	AMC	—	-1.37	—	2.78	+0.0%	-7.9%	-10.9%	+86.8%	-0.5%	+6.4%	—
May 13, 2025	AMC	—	-2.75	—	3.51	-0.6%	-6.6%	-4.9%	-2.9%	+266.3%	-38.0%	—
Mar 31, 2025	AMC	—	-3.36	—	2.73	-8.1%	+28.2%	-9.1%	+84.0%	-7.2%	-17.9%	—
Nov 14, 2024	AMC	—	-1.96	—	9.67	-5.3%	-10.5%	-6.1%	+0.1%	+2.5%	+2.2%	—
Aug 14, 2024	AMC	—	-5.04	—	8.90	-21.2%	-15.5%	-1.2%	+31.6%	+0.2%	-0.4%	—
May 15, 2024	AMC	—	-5.46	—	19.46	-6.5%	+7.2%	+0.7%	-4.0%	+11.1%	+12.5%	—
Apr 1, 2024	AMC	—	-5.32	—	24.36	-6.3%	-2.9%	-3.0%	+0.6%	-2.4%	-5.0%	—
Nov 14, 2023	AMC	—	-4.48	—	11.97	+1.5%	+0.0%	-5.3%	+4.9%	-2.4%	-3.6%	—
Aug 14, 2023	AMC	—	-3.92	—	27.30	+0.0%	+0.0%	-4.1%	+0.5%	+0.0%	+0.0%	—
May 15, 2023	AMC	—	-2.38	—	30.52	-1.4%	-9.6%	+1.0%	+4.5%	-3.8%	+7.0%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Oct 29	Maxim Group	Maintains	Buy → Buy	—	$100.80	$108.08	+7.2%	+4.4%	+5.9%	+2.5%	+0.0%	+1.0%

Data updated apr 28, 2026 6:33pm · Source: massive.com